Literature DB >> 27453044

CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.

Alexis Guernet1, Sathish Kumar Mungamuri2, Dorthe Cartier1, Ravi Sachidanandam2, Anitha Jayaprakash2, Sahil Adriouch3, Myriam Vezain4, Françoise Charbonnier4, Guy Rohkin2, Sophie Coutant4, Shen Yao2, Hassan Ainani1, David Alexandre1, Isabelle Tournier4, Olivier Boyer5, Stuart A Aaronson2, Youssef Anouar1, Luca Grumolato6.   

Abstract

Intratumor genetic heterogeneity underlies the ability of tumors to evolve and adapt to different environmental conditions. Using CRISPR/Cas9 technology and specific DNA barcodes, we devised a strategy to recapitulate and trace the emergence of subpopulations of cancer cells containing a mutation of interest. We used this approach to model different mechanisms of lung cancer cell resistance to EGFR inhibitors and to assess effects of combined drug therapies. By overcoming intrinsic limitations of current approaches, CRISPR-barcoding also enables investigation of most types of genetic modifications, including repair of oncogenic driver mutations. Finally, we used highly complex barcodes inserted at a specific genome location as a means of simultaneously tracing the fates of many thousands of genetically labeled cancer cells. CRISPR-barcoding is a straightforward and highly flexible method that should greatly facilitate the functional investigation of specific mutations, in a context that closely mimics the complexity of cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27453044      PMCID: PMC5537739          DOI: 10.1016/j.molcel.2016.06.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  51 in total

Review 1.  Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR.

Authors:  Michael Boettcher; Michael T McManus
Journal:  Mol Cell       Date:  2015-05-21       Impact factor: 17.970

2.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

Review 3.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

4.  Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.

Authors:  Van Trung Chu; Timm Weber; Benedikt Wefers; Wolfgang Wurst; Sandrine Sander; Klaus Rajewsky; Ralf Kühn
Journal:  Nat Biotechnol       Date:  2015-03-24       Impact factor: 54.908

5.  Small molecules enhance CRISPR genome editing in pluripotent stem cells.

Authors:  Chen Yu; Yanxia Liu; Tianhua Ma; Kai Liu; Shaohua Xu; Yu Zhang; Honglei Liu; Marie La Russa; Min Xie; Sheng Ding; Lei S Qi
Journal:  Cell Stem Cell       Date:  2015-02-05       Impact factor: 24.633

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

Authors:  Dominik Paquet; Dylan Kwart; Antonia Chen; Andrew Sproul; Samson Jacob; Shaun Teo; Kimberly Moore Olsen; Andrew Gregg; Scott Noggle; Marc Tessier-Lavigne
Journal:  Nature       Date:  2016-04-27       Impact factor: 49.962

8.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

9.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

10.  Targeted genomic rearrangements using CRISPR/Cas technology.

Authors:  Peter S Choi; Matthew Meyerson
Journal:  Nat Commun       Date:  2014-04-24       Impact factor: 14.919

View more
  22 in total

1.  Modeling intratumor heterogeneity through CRISPR-barcodes.

Authors:  Alexis Guernet; Stuart A Aaronson; Youssef Anouar; Luca Grumolato
Journal:  Mol Cell Oncol       Date:  2016-09-06

2.  CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.

Authors:  Federica Zito Marino; Marina Accardo; Renato Franco
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Whole-organism clone tracing using single-cell sequencing.

Authors:  Anna Alemany; Maria Florescu; Chloé S Baron; Josi Peterson-Maduro; Alexander van Oudenaarden
Journal:  Nature       Date:  2018-03-28       Impact factor: 49.962

Review 4.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

5.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

Review 6.  A view on drug resistance in cancer.

Authors:  José Baselga; David M Hyman; Neil Vasan
Journal:  Nature       Date:  2019-11-13       Impact factor: 49.962

Review 7.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

Review 8.  Role of the CRISPR system in controlling gene transcription and monitoring cell fate (Review).

Authors:  Stella Baliou; Maria Adamaki; Anthony M Kyriakopoulos; Demetrios A Spandidos; Michalis Panayiotidis; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Mol Med Rep       Date:  2017-11-16       Impact factor: 2.952

Review 9.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987

Review 10.  The frontier of live tissue imaging across space and time.

Authors:  Qiang Huang; Aliesha Garrett; Shree Bose; Stephanie Blocker; Anne C Rios; Hans Clevers; Xiling Shen
Journal:  Cell Stem Cell       Date:  2021-04-01       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.